cas 481681-02-1, 4-FLUORO-3-(HYDROXYMETHYL)BENZENEBORONIC ACID

Articles about 481681-02-1Total 4 be found

Article title
Article abstract
Author
Journal number and time
Download

PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR
Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.
-
Paragraph 0471-0473

(2021/12/18)

Controlled release system based on mesoporous silica nanoparticles and preparation method thereof
The invention relates to a meso-porous silicon oxide nanoparticle-based controlled release system and a preparation method thereof, and concretely relates to a meso-porous silicon oxide-based nanoparticle for controlled release, a controlled release system containing the nanoparticle, and a preparation method and a kit of the nanoparticle. The nanoparticle contains a phenyl borate functionalized meso-porous silicon oxide nanoparticle and a surface functionalized nanoparticle hole plugging agent which can be combined with phenyl borate. When no substrate exists, a nanometer silicon oxide system in the invention can realize zero early release; and after the substrate is added, a meso-porous tunnel plugged by the nanoparticle is opened in order to realize controlled release of a content. The method has the advantages of simple material synthesis, adjustable composition, and realization of responses to different substrates and different concentrations.
-
Paragraph 0153-0155

(2020/08/30)

PHOSPHONATE CONJUGATES AND USES THEREOF
Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.
-
Paragraph 00159; 00168-00169

(2020/07/31)

8-(BIARYL) QUINOLINE PDE4 INHIBITORS
8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues.In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.
-
Page 50

(2010/02/06)